This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
QR Pharma, Inc.
Drug Names(s): Phenserine
Description: Phenserine is a dual acetylcholinesterase and beta-amyloid precursor protein (B-APP) inhibitor. Acetylcholinesterase breaks down acetylcholine, a neurotransmitter important to memory and cognitive function. B-APP is the precursor to the main protein found in amyloid plaques, which are found in regions of neuronal loss in the brains of Alzheimer patients.
Axonyx and Daewoong - South Korea
In January 2006, Axonyx and Daewoong Pharmaceutical signed an exclusive license for the use of Phenserine in the South Korean market. Under the terms of the agreement Daewoong, at its own costs, undertakes to pursue the product development and regulatory work necessary for a New Drug Application (NDA) (or its equivalent) in South Korea with respect to Phenserine for the treatment of Alzheimer's disease (AD). The financial terms of the deal are confidential, but include royalty payments to Axonyx based on sales of Phenserine by Daewoong in the South Korean market.
Axonyx and TorreyPines
In June 2006, Axonyx and TorreyPines Therapeutics announced that they entered into a definitive merger agreement. This agreement was finalized in October 2006.
Cenomed and TorreyPines - Chemical Defense and Counterterrorism Defense
In October 2008, Cenomed BioSciences, LLC, a majority-owned subsidiary of Abraxis BioScience, and...See full deal structure in Biomedtracker
Partners: Daewoong Pharmaceutical Company Ltd. Raptor Pharmaceutical Corp. Cenomed BioSciences, LLC
Pink Sheet Axonyx continues phenserine evaluation
Pink Sheet Axonyx phenserine failed Phase III data
Additional information available to subscribers only: